Sartorius Stedim stock gains analyst support as Barclays raises target to 240 EUR

Published on 09/10/2026 at 18:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock drew attention after Barclays lifted its price target from 210 to 240 EUR on September 8, 2026 while keeping an Overweight rating. The shares closed at 186.30 EUR on Euronext Paris that day, around 28 percent below the new target and well above the 52-week low.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech SA stock (ISIN FR0013154002) traded firmly on Euronext Paris after Barclays raised its price target from 210 to 240 EUR on September 8, 2026 while reiterating an Overweight rating, with the shares closing that day at 186.30 EUR and thus about 28 percent below the new target.

Barclays raises target and reiterates Overweight

According to ad-hoc-news, Barclays increased its price target for Sartorius Stedim Biotech SA on September 8, 2026 from 210 to 240 EUR and confirmed its Overweight recommendation for the stock, highlighting a more optimistic view on the company’s medium-term earnings power.

As ad-hoc-news reports, the new 240 EUR target is around 14.3 percent above the previous 210 EUR level, while the closing price of 186.30 EUR on Euronext Paris that day left an upside gap of about 28.7 percent to the revised target, underlining the potential that Barclays sees in the shares compared with the current market pricing.

Stock price positioned between 52-week low and high

In the same overview, ad-hoc-news states that Sartorius Stedim Biotech SA shares on Euronext Paris at the close on September 8, 2026 were trading clearly above their 52-week low of 150.90 EUR but also noticeably below the 52-week high of 223.30 EUR, positioning the current level roughly in the middle of the recent range.

The same report from ad-hoc-news notes that the stock rose from 183.30 EUR to 186.30 EUR between September 7 and September 8, 2026, corresponding to a one-day gain of about 1.6 percent, which suggests that the market reacted positively to the Barclays target revision and rating confirmation.

Medium-term targets and dividend policy in focus

Beyond the immediate reaction to Barclays, investors in Sartorius Stedim Biotech SA stock are also looking at the company’s medium-term targets and balance-sheet indicators. A profile of the company published by Fortuneo describes a controlled financial situation at the end of a recent September period, with an equity ratio of 39.7 percent and a leverage ratio of 3.7 times, figures which indicate a significant but manageable use of debt for growth.

According to the same company profile on Fortuneo, Sartorius Stedim Biotech SA reported an increase of about 7 percent in sales and 13 percent in EBITDA by the end of a recent September period, prompting the company to raise its objectives for 2025 to target revenue growth of roughly 7 percent and an operating margin slightly above 29.5 percent, while keeping a longer-term 2028 margin goal above 30 percent.

The same overview from Fortuneo adds that the integration of Polyplus, a specialist in transfection reagents and plasmid DNA, is expected to contribute around 20 percent of Sartorius Stedim Biotech’s revenues, while the company plans to maintain a distribution rate of 16.7 percent, implying a stable dividend of 0.69 EUR for fiscal year 2024.

Stock valuation and investor takeaway

From an investor perspective, the combination of Barclays’ higher price target of 240 EUR and the current trading level around 186.30 EUR as of September 8, 2026 suggests that the market has not yet fully priced in the medium-term growth and margin ambitions described in the Fortuneo profile, which include a targeted operating margin above 29.5 percent in 2025 and above 30 percent by 2028.

At the same time, the leverage ratio of 3.7 times at a recent period end, as cited by Fortuneo, underlines that Sartorius Stedim Biotech SA is using debt to fund expansion, but the equity ratio of 39.7 percent provides a buffer that many investors may view as acceptable in a high-growth life-science tools business.

Current reference price and market context

On its primary listing venue Euronext Paris, Sartorius Stedim Biotech SA stock most recently closed at 186.30 EUR on September 8, 2026, placing it well above the 52-week low of 150.90 EUR but still appreciably below the 52-week high of 223.30 EUR, and leaving an upside gap of close to 28 percent to the 240 EUR price target set by Barclays.